Inclisiran, a Potent Lipid Lowering Treatment for Reaching LDL Goals on Top of Statins and Ezetimibe: A Single User Experiences DOI Open Access
Tomaž Zupanc,

Jurij Krajačič,

Boris Krajačič

et al.

South East European Journal of Cardiology, Journal Year: 2024, Volume and Issue: 5, P. 30 - 33

Published: Nov. 17, 2024

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality, reducing LDL cholesterol key strategy in lowering risk. Inclisiran, small interfering RNA that targets PCSK9, an effective lipid-lowering treatment. AIM: This study evaluates the long-term efficacy inclisiran patients with high risk who fail to reach goals despite statin ezetimibe therapy. METHODS: A total 33 high-risk atherosclerotic elevated levels, maximal statin/ezetimibe therapy or couldn't tolerate statins, were administered at baseline 21 receiving second dose 3 months. Lipid profiles measured baseline, months after first dose, dose. The primary outcome was change LDL-C levels from post-treatment. RESULTS: Inclisiran significantly reduced mean 2.66 mmol/L 1.49 (p < 0.001). 73.0% achieved below 1.8 mmol/L, 57.7% 1.4 34.6% 1.0 42.3% experiencing reduction more than 50% These reductions maintained remaining lower baseline. CONCLUSION: provides significant sustained represents treatment option for

Language: Английский

Phytosterol-Enriched Dietary Supplements for Lowering Plasma LDL-Cholesterol: Yes or No? DOI Open Access
Frans Stellaard, Dieter Lütjohann

Nutrients, Journal Year: 2025, Volume and Issue: 17(4), P. 654 - 654

Published: Feb. 12, 2025

Elevated plasma low-density lipoprotein cholesterol (LDL-C) is associated with an increased risk for atherosclerosis and development of cardiovascular disease. An elevated LDL-C concentration the result enhanced C synthesis, absorption, and/or altered homeostasis. Plasma lowering can be achieved using pharmaceutical means. Statin therapy inhibits endogenous synthesis leads to a mean 40% reduction. Ezetimibe absorption achieves average 20% reduction 10 mg daily intake. Phytosterol established by dietary supplements enriched in phytosterols phytostanols. A dosage 2 3 g day reduces 10% This expresses 10-fold intake or 100-fold Phytosterol- -stanol-enriched are freely available supermarket. The majority consumers may healthy subjects normal range. Scientific evidence reveals that phytosterol atherosclerosis. degree dependent on patient’s genetic polymorphisms NPC1L1 ABCG5/G8 transport proteins as well due lowering. Subjects only slightly have minimal lack compensation potential phytosterols.

Language: Английский

Citations

0
Schlagen Frauenherzen anders? – Geschlechterunterschiede im Lipidmanagement DOI Creative Commons

Maximilian A. Muck,

Andrea Baessler

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Zusammenfassung Geschlechterspezifische Unterschiede im Lipidstoffwechsel sind vor allem hormonell bedingt. Frauen haben prämenopausal Vergleich zu Männern tendenziell günstigere Lipidwerte, wie höhere Konzentrationen an High-Density-Lipoprotein-Cholesterin (HDL-C) und niedrigere Low-Density-Lipoprotein-Cholesterin (LDL-C). Mit Beginn der Menopause verschlechtern sich diese Werte jedoch durch hormonelle Veränderungen, wodurch bei das Risiko für atherosklerotische Herz-Kreislauf-Erkrankungen erhöht. Trotz vergleichbarer Wirksamkeit lipidsenkender Therapien zeigen mehrere Studien einheitlich, dass seltener die empfohlenen LDL-C-Zielwerte erreichen. Besonders in klinischen Praxis bestehen große Diskrepanzen zwischen Leitlinienempfehlungen tatsächlicher Behandlung, Hochrisikopatientinnen. Verschiedene Barrieren tragen wesentlich dazu bei: Dazu gehören Unterschätzung des Risikos behandelnde Ärzte, ein zurückhaltenderes Verordnungsverhalten, eingeschränktes Bewusstsein Notwendigkeit einer Therapie Patientinnen sowie eine verminderte Medikamentenadhärenz. Letztere wird unter anderem stärkere Wahrnehmung von Nebenwirkungen Prävalenz Statinintoleranz beeinflusst. Die Betreuung spezialisierten Lipidzentren zeigt, viele schwer einstellbare Patienten, z. B. Patienten mit oder hohen LDL-C-Ausgangswerten, gezielter Nachsorge erfolgreich behandelt werden können. Neue pharmakologische Ansätze Kombinationstherapien ermöglichen es, Therapieziele Dennoch erreichen trotz solcher Maßnahmen ihre LDL-Zielwerte, was auf intensiverer geschlechtersensibler Strategien hinweist. Eine wirksame Lipidtherapie erfordert verstärkt den Einsatz Kombinationstherapien, regelmäßige Kontrollen enge Zusammenarbeit Patient Arzt. ist es entscheidend, Therapieadhärenz verbessern mögliche konsequent anzugehen, um kardiovaskuläre effektiv senken.

Citations

0
Clinical Utilization and Performance of Bempedoic Acid in an Italian Real-World Setting: Insight from Campania Region DOI Open Access
Vincenzo Russo,

G Ratti,

Antonio Parrella

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1839 - 1839

Published: March 9, 2025

Background/Objectives: Bempedoic acid (BA) is a novel lipid-lowering agent that reduces low-density lipoprotein cholesterol (LDL-c) and cardiovascular events. Limited real-world data on its effectiveness safety are available. This study aimed to evaluate the utilization clinical performance of BA in routine practice. Moreover, an explorative pharmacoeconomic analysis was performed. Methods: We prospectively enrolled consecutive patients with dyslipidemia who started 180 mg BA, alone or 10 ezetimibe, across five outpatient clinics Campania Region, Italy from September December 2023. Clinical laboratory assessments, including lipid profile, hepatic function, creatine phosphokinase levels, were performed at baseline least after one month follow-up. Side effects recorded. Results: 111 (age 65 ± 9 years, 61% male) included. At initiation, 70.3% maximally tolerated statin dosage 16.2% ezetimibe alone, 13.5% PCSK9 inhibitors due intolerance. significantly reduced LDL-c serum levels (89.9 33.0 vs. 56 27.6 mg/dL; p < 0.0001), 46% achieving therapeutic targets. decreased by 28% intensive statins/ezetimibe 45% statin-intolerant patients, healthcare costs. infrequent (10%) reversible. Adherence 99%, persistence 90%. Conclusions: In our pratice, primarily used high-risk failed reach target statins/ezetimibe, lesser extent, individuals. treatment enabled 54% target. well tolerated, showed high adherence persistence, contributing cost savings.

Language: Английский

Citations

0
Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis DOI
Maciej Banach, Vikash Jaiswal, Song Peng Ang

et al.

Mayo Clinic Proceedings, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Stellungnahme zur kritischen Bewertung der Nationalen VersorgungsLeitlinie zur chronischen koronaren Herzerkrankung DOI
Julinda Mehilli, Lars Eckardt, Ulrich Laufs

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Die nationalen Versorgungsleitlinien geben Empfehlungen zur Diagnostik und Therapie, die auf aktuellen, repräsentativen methodisch hochwertigen Studien basieren klinische Realität in Deutschland widerspiegeln sollen, um patientenzentrierte Handlungsempfehlungen zu bieten. aktuelle NVL chronischen koronaren Herzerkrankung (NVL-CCS) erfüllt diese Anforderungen jedoch nur unzureichend. Im Widerspruch wissenschaftlichen Evidenz den Europäischen Leitlinien wird der NVL-CCS ungenaue Marburger Herz-Score Einschätzung Wahrscheinlichkeit einer stenosierenden verwendet, ebenso wie eine feste Dosisstrategie cholesterinsenkenden Statintherapie. prognostischen Vorteile Myokardrevaskularisation werden verneint, Auswahl Modalität bei komplexer KHK beruhen unkritischen möglicherweise voreingenommenen Interpretation vorhandenen Evidenz. Entscheidungshilfen für Patienten, invasive Koronarangiographie oder benötigen, sind weder evidenzbasiert noch praxisnah wirken häufig verwirrend. Vor diesem Hintergrund haben DGK, DGIM DGRM beschlossen, nicht konsentieren regen Überarbeitung an.

Citations

0
Association Between Cardiovascular Risk Assessed by the SCORE System and Cardiac Computed Tomography-Derived Left Atrioventricular Coupling Index DOI Creative Commons

Przemysław Cheładze,

Michał Fułek, Katarzyna Fułek

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(9), P. 1075 - 1075

Published: April 24, 2025

Background/Objectives: Recent advancements in cardiovascular imaging have opened new avenues for integrating novel biomarkers into risk assessment models, enhancing their predictive accuracy. One such emerging biomarker is the left atrioventricular coupling index (LACI). The study aims to evaluate relationship between SCORE (Systematic Coronary Risk Evaluation) and LACI derived from cardiac computed tomography (CCT). Methods: This included 137 participants (56.09 ± 7.64 years). Cardiovascular was assessed using system. CCT performed standard coronary angiography protocol. calculated as ratio of atrial end-diastolic volume (LA EDV) ventricular (LV EDV), expressed a percentage. Results: subgroup with ≥5% had higher than < 5%. Similarly, ≥10% 10%. demonstrated significant positive correlation (r = 0.29, p 0.01). Prediction analysis showed that ≥ 53.34% predictor 10% highest accuracy 78.1%, high sensitivity 79.8% moderate specificity 61.5%. High (80.6%) characterized by 29.52% 5. Conclusions: associated risk, reflected its

Language: Английский

Citations

0
Current landscape of dyslipidemia-related randomized clinical trials registered on the International Clinical Trials Registry Platform DOI Creative Commons
Ling Pei, Ming Su,

Reyihannisha Yakeya

et al.

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 13

Published: May 1, 2025

Introduction This study elucidates the characteristics of randomized clinical trials (RCTs) related to dyslipidemia that are registered on International Clinical Trials Registry Platform (ICTRP) better identify research hotspots, address existing gaps, and improve trial designs. Methods cross-sectional included dyslipidemia-related RCTs ICTRP up 13 August 2024. We evaluated relevant these reviewed their publication status after enrollment using PubMed. Results A total 2,410 were analyzed. The number sharply increased in 2005 ( N = 125). majority adults (91.4%), with a median sample size 93 (50–229), 92.9% had no sex-based restrictions. Few focused participants aged ≤18 years (2.8%), those 19–44 (3.4%), or exclusively women (2.8%). Medication (83.1%) was most common type intervention. Efficacy safety outcomes predominant (81.5%), while only 0.7% specified treatment adherence as primary outcome. involving larger sizes (median 100.0 [50, 245] vs. 56.0 [27, 108], p 0.047) lower proportions natural medicine extracts (26.6% 33.6%, &lt; 0.001) compared age-specific RCTs. After enrollment, 7-year cumulative rate 20.8%. Conclusions High-quality younger participants, women, adherence-related lacking. Researchers should prioritize exploring novel therapeutic strategies rates.

Language: Английский

Citations

0
Looking Back, Leaning Forward—A Contemporary Overview of Acute Coronary Syndrome DOI Open Access
Alexander Fardman, Fernando Chernomordik,

Roy Beigel

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(23), P. 7331 - 7331

Published: Dec. 2, 2024

Cardiovascular disease (CVD) remains the most common cause of morbidity and mortality worldwide [...].

Language: Английский

Citations

0
Inclisiran, a Potent Lipid Lowering Treatment for Reaching LDL Goals on Top of Statins and Ezetimibe: A Single User Experiences DOI Open Access
Tomaž Zupanc,

Jurij Krajačič,

Boris Krajačič

et al.

South East European Journal of Cardiology, Journal Year: 2024, Volume and Issue: 5, P. 30 - 33

Published: Nov. 17, 2024

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality, reducing LDL cholesterol key strategy in lowering risk. Inclisiran, small interfering RNA that targets PCSK9, an effective lipid-lowering treatment. AIM: This study evaluates the long-term efficacy inclisiran patients with high risk who fail to reach goals despite statin ezetimibe therapy. METHODS: A total 33 high-risk atherosclerotic elevated levels, maximal statin/ezetimibe therapy or couldn't tolerate statins, were administered at baseline 21 receiving second dose 3 months. Lipid profiles measured baseline, months after first dose, dose. The primary outcome was change LDL-C levels from post-treatment. RESULTS: Inclisiran significantly reduced mean 2.66 mmol/L 1.49 (p < 0.001). 73.0% achieved below 1.8 mmol/L, 57.7% 1.4 34.6% 1.0 42.3% experiencing reduction more than 50% These reductions maintained remaining lower baseline. CONCLUSION: provides significant sustained represents treatment option for

Language: Английский

Citations

0